Rapport Therapeutics (RAPP) Operating Expenses (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Operating Expenses data on file, last reported at $44.2 million in Q1 2026.

• On a quarterly basis, Operating Expenses rose 63.11% year-over-year to $44.2 million in Q1 2026; TTM through Mar 2026 was $142.2 million, a 52.8% increase from a year earlier, with the FY2025 full-year figure at $125.1 million, up 50.62% from the prior year.
• Operating Expenses for Q1 2026 stood at $44.2 million, up from $38.5 million in the prior quarter.
• Over the last five years, Operating Expenses for RAPP reached as high as $44.2 million in Q1 2026 and fell as low as $6.6 million in Q2 2023.
• Historically, Operating Expenses has averaged $23.6 million across 4 years, with a median of $22.6 million in 2024.
• Across the five-year window, Operating Expenses surged 213.73% in 2024 and jumped 38.57% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $14.8 million in 2023, then surged by 58.99% to $23.5 million in 2024, then jumped by 63.72% to $38.5 million in 2025, then advanced by 14.82% to $44.2 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $44.2 million in Q1 2026, $38.5 million in Q4 2025, and $30.0 million in Q3 2025.